Literature DB >> 18632924

Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay.

Jane Steele1, Stuart Collins, Kaisheng Wen, Gordon Ryan, Christothea Constandinou-Williams, Ciaran B J Woodman.   

Abstract

We have evaluated a neutralizing antibody assay which uses human papillomavirus (HPV) type 16 (HPV-16) and HPV-18 pseudovirions carrying a secretory alkaline phosphatase reporter gene and which can potentially measure functionally relevant HPV type-specific neutralizing antibodies. The reproducibility of the assay was excellent; for HPV-16, the intra- and interassay kappa values were 0.95 and 0.90, respectively; and for HPV-18, the corresponding values were 0.90 and 0.90. This assay was used to describe the kinetics of the neutralizing antibody response in a cohort of 42 young women who were recruited soon after first intercourse and who first tested positive for HPV-16 DNA or HPV-18 DNA, or both, during follow-up. Most women seroconverted following the first detection of type-specific HPV DNA and remained seropositive until the end of follow-up. Our findings are broadly consistent with those of two other cohort studies which have measured the serological response following an incident infection by using the technically simpler virus-like-particle-based enzyme-linked immunosorbent assay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632924      PMCID: PMC2546683          DOI: 10.1128/CVI.00013-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  9 in total

1.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

Authors:  J J Carter; L A Koutsky; J P Hughes; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

2.  High incidence of cervical human papillomavirus infection in women during their first sexual relationship.

Authors:  Stuart Collins; Saeideh Mazloomzadeh; Heather Winter; Penny Blomfield; Andrew Bailey; Lawrence S Young; Ciaran B J Woodman
Journal:  BJOG       Date:  2002-01       Impact factor: 6.531

3.  Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

Authors:  C B Woodman; S Collins; H Winter; A Bailey; J Ellis; P Prior; M Yates; T P Rollason; L S Young
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

4.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

5.  Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  Methods Mol Med       Date:  2005

6.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

7.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

8.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Authors:  Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky
Journal:  Am J Epidemiol       Date:  2003-02-01       Impact factor: 4.897

9.  Natural history of human papillomavirus type 16 virus-like particle antibodies in young women.

Authors:  Gloria Y F Ho; Yevgeniy Y Studentsov; Robert Bierman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-01       Impact factor: 4.254

  9 in total
  7 in total

1.  Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.

Authors:  Brenda Y Hernandez; Thien Ton; Yurii B Shvetsov; Marc T Goodman; Xuemei Zhu
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

2.  Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia.

Authors:  Mel Krajden; Karuna Karunakaran; Stacy So; Joel M Palefsky; Rachna Sharma; Darrel Cook; Amanda Yu; Ron Chow; Simon Dobson; Gina S Ogilvie; Martin Petric
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

3.  Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia.

Authors:  Hiroyuki Ochi; Kazunari Kondo; Koji Matsumoto; Akinori Oki; Toshiharu Yasugi; Reiko Furuta; Yasuo Hirai; Hiroyuki Yoshikawa; Tadahito Kanda
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

4.  Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic.

Authors:  Eva Hamsikova; Viera Ludvikova; Jana Stasikova; Ruth Tachezy
Journal:  Sex Transm Infect       Date:  2012-06-08       Impact factor: 3.519

5.  Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection.

Authors:  Henrike J Vriend; Johannes A Bogaards; Fiona R M van der Klis; Mirte Scherpenisse; Hein J Boot; Audrey J King; Marianne A B van der Sande
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

6.  Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile.

Authors:  Felipe A Castro; Angelica Dominguez; Klaus Puschel; Vanessa Van De Wyngard; Peter J F Snijders; Silvia Franceschi; Michael Pawlita; Catterina Ferreccio
Journal:  BMC Infect Dis       Date:  2014-07-03       Impact factor: 3.090

7.  A cross-sectional study on the concordance between vaginal HPV DNA detection and type-specific antibodies in a multi-ethnic cohort of women from Amsterdam, the Netherlands - the HELIUS study.

Authors:  Alexandra Kovaleva; Catharina J Alberts; Tim Waterboer; Angelika Michel; Marieke B Snijder; Wilma Vermeulen; Liza Coyer; Maria Prins; Maarten Schim van der Loeff
Journal:  BMC Infect Dis       Date:  2016-09-22       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.